Moody’s stellt Pfizer-Rating auf den Prüfstand

FRANKFURT (Dow Jones)–Die Ratingagentur Moody’s stellt ihr Langfristrating “A1” für die Pfizer Inc auf den Prüfstand. …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
604